LAG3 and hematologic disorder: In a previous study, researchers studied the safety, tolerability, dose-limiting toxicity, maximum tolerated dose (MTD), and antitumor activity of MGD013 (which is an experimental bispecific molecule designed to bind PD-1 and LAG-3) in patients with advanced solid and hematological malignancies, and MGD013 synergistically blocked PD-1 and LAG-3 with acceptable safety and preliminary evidence of antitumor activity [84].